{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T14:40:32Z","timestamp":1648564832804},"reference-count":0,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1645,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CA: A Cancer Journal for Clinicians"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.3322\/caac.20110","type":"journal-article","created":{"date-parts":[[2011,3,4]],"date-time":"2011-03-04T04:11:53Z","timestamp":1299211913000},"page":"65-66","source":"Crossref","is-referenced-by-count":2,"title":["Discontinuation of imatinib may be possible in chronic myelogenous leukemia"],"prefix":"10.1002","volume":"61","author":[{"given":"Mary Kay","family":"Barton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,3,4]]},"container-title":["CA: A Cancer Journal for Clinicians"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.3322%2Fcaac.20110","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2017,3,30]],"date-time":"2017-03-30T02:40:15Z","timestamp":1490841615000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.3322\/caac.20110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":0,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,3]]}},"URL":"https:\/\/doi.org\/10.3322\/caac.20110","relation":{},"ISSN":["0007-9235"],"issn-type":[{"value":"0007-9235","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}